Recent announcements from the EPA and U.S. Department of Health and Human Services signal a significant shift in how emerging contaminants will be addressed in the United States. For the first time, the EPA has added microplastics and pharmaceuticals to its Contaminant Candidate List (CCL 6). While inclusion does not immediately create new regulations, it is a critical step that drives future research, monitoring, and potential rulemaking under the Safe Drinking Water Act. In practical terms, this means utilities and industrial water users should expect increased scrutiny, evolving guidance, and, eventually, regulatory consideration of these contaminants.
In parallel, HHS has launched a new research initiative (STOMP) focused on measuring, understanding, and ultimately removing microplastics from the human body. This reinforces the growing federal focus on both environmental presence and human health impacts.
What this means for U.S. Water clients:
- Increased monitoring expectations for emerging contaminants, including microplastics and pharmaceuticals
- Potential future regulatory requirements that may impact treatment processes and compliance strategies
- Heightened stakeholder and public interest in water quality transparency
- Opportunities to proactively assess treatment capabilities and prepare for evolving standards
Contact U.S. Water For Guidance
As the regulatory landscape continues to develop, early evaluation and planning will be key to staying ahead of requirements and maintaining system performance. U.S. Water is actively tracking these developments and can help you assess potential impacts, evaluate treatment options, and prepare for what’s ahead. Contact U.S. Water today to start the conversation.